Semaglutide modulates pro-inflammatory neutrophil phenotype induced by supraphysiological levels of the adipokine FABP4 in patients with cardiovascular disease.

31 August 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Antidiabetic drugs for treatment of cardiovascular disease Lipid Metabolism, Metabolic Syndrome, Diabetes ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology